ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Rituximab, Lenalidomide, and Ibrutinib as Frontline Therapy in Follicular Lymphoma: Results of the ALLIANCE 051103 Phase 1 Study

Conference Correspondent - ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Ongoing clinical efforts are focused on evaluating the efficacy and tolerability of targeted therapies in patients with follicular lymphoma (FL). Previous trials have separately demonstrated the safety and antitumor activity of the combination of rituximab with the immunomodulatory drug lenalidomide [ Read More ]

Outcomes of Ibrutinib Treatment in Patients with Relapsed or Refractory CLL/SLL with del17p in the RESONATE-17 Study

Conference Correspondent - ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Patients with chronic lymphocytic leukemia (CLL) harboring deletion 17p (del17p) cytogenetic abnormalities are associated with poor prognosis, and show suboptimal responses to chemoimmunotherapy, underscoring the need for novel treatment strategies. Ibrutinib is a first-in-class, oral inhibitor of Bruton’s tyrosine kinase [ Read More ]

Ibrutinib versus Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle-Cell Lymphoma (MCL)

Conference Correspondent - ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Ibrutinib is a first-in-class, oral, covalent inhibitor of Bruton’s tyrosine kinase that is approved for treatment of patients with mantle-cell lymphoma (MCL) who have received at least 1 prior therapy.1 In 2 single-arm phase 2 trials, single-agent ibrutinib treatment resulted [ Read More ]

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Phase 2 Study

Conference Correspondent - ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Follicular lymphoma (FL) is an indolent type of non-Hodgkin lymphoma that is not cured with standard chemoimmunotherapeutic regimens incorporating the anti-CD20 monoclonal antibody rituximab. Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton’s tyrosine kinase, has shown activity in a phase [ Read More ]

Obinutuzumab plus Bendamustine in Previously Untreated Patients with CLL: Subgroup Analysis of the Phase 3 GREEN Study

Conference Correspondent - ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Obinutuzumab is a glycoengineered anti-CD20 monoclonal antibody that showed superior survival outcomes in combination chlorambucil compared with chlorambucil alone and with an acceptable safety profile in patients with chronic lymphocytic leukemia (CLL) in the CLL11 study.1 GREEN is an ongoing, [ Read More ]

Ibrutinib versus Chlorambucil in Patients ?65 Years with Treatment-Naïve CLL/SLL: Results from the Phase 3 RESONATE-2 Study

Conference Correspondent - ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Standard chemoimmunotherapy regimens are often not tolerated by the majority of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who are typically older patients with considerable comorbidities and disease-related immunosuppression. Treatment options for this patient population are limited; they are [ Read More ]

Obinutuzumab plus Ibrutinib as Induction and Maintenance Therapy After Bendamustine Debulking in Patients with CLL: Interim Results of a Phase 2 CLL2-BIG Trial

Conference Correspondent - ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Obinutuzumab is a glycoengineered anti-CD20 monoclonal antibody that showed superior survival outcomes in combination chlorambucil compared with chlorambucil alone in patients with chronic lymphocytic leukemia (CLL).1 Ibrutinib is a first-in-class, oral, covalent inhibitor of Bruton’s tyrosine kinase that is approved [ Read More ]